Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blinded, Parallel Group, Randomized Trial-Reference-Cited by-同舟云学术

Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blinded, Parallel Group, Randomized Trial

Published:2015-08-17 Issue: Volume: Page:dc151025
ISSN:0149-5992
Container-title:Diabetes Care
language:en
Short-container-title:Dia Care

Author:

Idorn Thomas,Knop Filip K.,Jørgensen Morten B.,Jensen Tonny,Resuli Marsela,Hansen Pernille M.,Christensen Karl B.,Holst Jens J.,Hornum Mads,Feldt-Rasmussen Bo

Funder

Novo Nordisk

Publisher

American Diabetes Association

Subject

Advanced and Specialised Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Kidney Transplant Candidacy: Addressing Common Medical and Psychosocial Barriers to Transplant;Advances in Kidney Disease and Health;2024-09

2. From diabetes to diverse domains: the multifaceted roles of GLP-1 receptor agonists;Molecular Biology Reports;2024-07-23

3. Response to “Experience with dulaglutide in an obese diabetic patient on incremental peritoneal dialysis”. Response to related letter;Nefrología (English Edition);2024-05

4. Glucagon‐like peptide‐1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta‐analysis and meta‐regression;Diabetes, Obesity and Metabolism;2024-03-20

5. The impact of GLP-1 receptor agonist liraglutide on blood pressure profile, hydration, natriuresis in diabetic patients with severely impaired kidney function;Scientific Reports;2024-02-29